Andre Goy, M.D., M.S., is Chairman and Director of John Theurer Cancer Center (JTCC) at Hackensack University Medical Center. As Chief of the Division of Lymphoma, he leads New Jersey’s largest program for lymphoma. Dr. Goy has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris, and the Pasteur Institute in Paris
He is widely known his work on mantle cell lymphoma (MCL) and was lead/co investigator for the development of all 4 FDA-approved drugs in MCL (bortezomib, lenalidomide, and ibrutinib and acalabrutinib). He believes that a revolution is happening in cancer medicine, driven by cell-based therapies and precision medicine. Under Dr. Goy's direction, JTCC became one of the few sites in the country offering chimeric antigen receptor (CAR) T-cell therapy—a highly promising immunotherapy for certain blood cancers. Dr. Goy was instrumental in developing JTCC's Tissue Bank, where samples are stored and analyzed for research. JTCC has also grown to become one of the largest bone marrow transplant programs in the Tri-State area. Dr Goy has published extensively and serves as reviewer for many journals in the field of hematology and oncology research including JCO, Blood, Cancer and the NEJM.
Dr Goy is Professor of Medicine at Georgetown University and Founding Char at Seton Hall University, Co-founder of COTA. Member of SAB, for LRF and NCI study group on lymphoma; World Economic Forum. Co-Chair, of Global Future Council on Global Health and Healthcare.